Tokyo Tape
Sign in
← Tohoku Chemical

Quarterly report · Q3

7446.TEDINET S100RLXQ
Period2022-10-01 → 2023-06-30
Filed2023-08-10
StandardJapan GAAP
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 33
MetricValuePeriodScopeSource row
Revenue¥26.9bn2022-10-01 → 2023-06-30Cons.Net sales
Revenue¥37.3bn2021-10-01 → 2022-09-30Cons.Net sales (5-year summary)
Revenue¥27.9bn2021-10-01 → 2022-06-30Cons.Net sales
Operating income¥659m2022-10-01 → 2023-06-30Cons.Operating income
Operating income¥763m2021-10-01 → 2022-06-30Cons.Operating income
Ordinary income¥708m2022-10-01 → 2023-06-30Cons.Ordinary income
Ordinary income¥1.0bn2021-10-01 → 2022-09-30Cons.Ordinary income loss (5-year summary)
Ordinary income¥814m2021-10-01 → 2022-06-30Cons.Ordinary income
Profit before tax¥707m2022-10-01 → 2023-06-30Cons.Income before income taxes
Profit before tax¥786m2021-10-01 → 2022-06-30Cons.Income before income taxes
Net income (owners)¥499m2022-10-01 → 2023-06-30Cons.Profit loss attributable to owners of parent
Net income (owners)¥658m2021-10-01 → 2022-09-30Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)¥539m2021-10-01 → 2022-06-30Cons.Profit loss attributable to owners of parent
Net income¥507m2022-10-01 → 2023-06-30Cons.Profit loss
Net income¥559m2021-10-01 → 2022-06-30Cons.Profit loss
Total assets¥17.8bnat 2023-06-30Cons.Assets
Total assets¥17.5bnat 2022-09-30Cons.Assets
Total assets¥15.0bnat 2022-06-30Cons.Total assets (5-year summary)
Total liabilities¥10.5bnat 2023-06-30Cons.Liabilities
Total liabilities¥10.8bnat 2022-09-30Cons.Liabilities
Net assets / equity¥7.2bnat 2023-06-30Cons.Net assets
Net assets / equity¥6.7bnat 2022-09-30Cons.Net assets
Net assets / equity¥6.6bnat 2022-06-30Cons.Net assets (5-year summary)
Cash and deposits¥1.4bnat 2023-06-30Cons.Cash and deposits
Cash and deposits¥1.4bnat 2022-09-30Cons.Cash and deposits
EPS (basic)¥553.842022-10-01 → 2023-06-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥146.632023-04-01 → 2023-06-30dCons.Basic earnings loss per share (5-year summary)
EPS (basic)¥728.762021-10-01 → 2022-09-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥596.992021-10-01 → 2022-06-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥185.032022-04-01 → 2022-06-30dCons.Basic earnings loss per share (5-year summary)
Equity ratio40.3%at 2023-06-30Cons.Equity to asset ratio (5-year summary)
Equity ratio37.7%at 2022-09-30Cons.Equity to asset ratio (5-year summary)
Equity ratio43.2%at 2022-06-30Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 20
SegmentItemPeriodValue
Otherother segmentsrevenue2022-10-01 → 2023-06-30¥313m
Otherother segmentsrevenue external2022-10-01 → 2023-06-30¥313m
jpcrp040300-q3r_E02810-000Foodreportable segmentrevenue2022-10-01 → 2023-06-30¥2.5bn
jpcrp040300-q3r_E02810-000Foodreportable segmentrevenue external2022-10-01 → 2023-06-30¥2.5bn
jpcrp040300-q3r_E02810-000Pharmaceutical Productsreportable segmentrevenue2022-10-01 → 2023-06-30¥13.5bn
jpcrp040300-q3r_E02810-000Pharmaceutical Productsreportable segmentrevenue external2022-10-01 → 2023-06-30¥13.5bn
jpcrp040300-q3r_E02810-000Reagent For Clinical Testreportable segmentrevenue2022-10-01 → 2023-06-30¥10.6bn
jpcrp040300-q3r_E02810-000Reagent For Clinical Testreportable segmentrevenue external2022-10-01 → 2023-06-30¥10.6bn
Total Of Reportable Segments And Otherssegment totalrevenue2022-10-01 → 2023-06-30¥26.9bn
Total Of Reportable Segments And Otherssegment totalrevenue external2022-10-01 → 2023-06-30¥26.9bn
Otherother segmentsrevenue2021-10-01 → 2022-06-30¥318m
Otherother segmentsrevenue external2021-10-01 → 2022-06-30¥318m
jpcrp040300-q3r_E02810-000Foodreportable segmentrevenue2021-10-01 → 2022-06-30¥2.4bn
jpcrp040300-q3r_E02810-000Foodreportable segmentrevenue external2021-10-01 → 2022-06-30¥2.4bn
jpcrp040300-q3r_E02810-000Pharmaceutical Productsreportable segmentrevenue2021-10-01 → 2022-06-30¥13.8bn
jpcrp040300-q3r_E02810-000Pharmaceutical Productsreportable segmentrevenue external2021-10-01 → 2022-06-30¥13.8bn
jpcrp040300-q3r_E02810-000Reagent For Clinical Testreportable segmentrevenue2021-10-01 → 2022-06-30¥11.4bn
jpcrp040300-q3r_E02810-000Reagent For Clinical Testreportable segmentrevenue external2021-10-01 → 2022-06-30¥11.4bn
Total Of Reportable Segments And Otherssegment totalrevenue2021-10-01 → 2022-06-30¥27.9bn
Total Of Reportable Segments And Otherssegment totalrevenue external2021-10-01 → 2022-06-30¥27.9bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 382
ItemContextValueUnit
Valuation difference on available for sale securitiesPrior1YearInstant579755000JPY
Valuation difference on available for sale securitiesCurrentQuarterInstant728869000JPY
Remeasurements of defined benefit plansPrior1YearInstant-1499000JPY
Remeasurements of defined benefit plansCurrentQuarterInstant-222000JPY
Valuation and translation adjustmentsPrior1YearInstant578255000JPY
Valuation and translation adjustmentsCurrentQuarterInstant728646000JPY
Non controlling interestsPrior1YearInstant76384000JPY
Non controlling interestsCurrentQuarterInstant84115000JPY
Net assetsPrior1YearInstant6681448000JPY
Net assetsCurrentQuarterInstant7234976000JPY
Liabilities and net assetsPrior1YearInstant17519610000JPY
Liabilities and net assetsCurrentQuarterInstant17755661000JPY
Net salesPrior1YTDDuration27901693000JPY
Net salesCurrentYTDDuration26933249000JPY
Cost of salesPrior1YTDDuration25319443000JPY
Cost of salesCurrentYTDDuration24400422000JPY
Gross profitPrior1YTDDuration2582250000JPY
Gross profitCurrentYTDDuration2532827000JPY
Selling general and administrative expensesPrior1YTDDuration1818758000JPY
Selling general and administrative expensesCurrentYTDDuration1874261000JPY
Operating incomePrior1YTDDuration763491000JPY
Operating incomeCurrentYTDDuration658566000JPY
Interest income noiPrior1YTDDuration2295000JPY
Interest income noiCurrentYTDDuration2485000JPY
Dividends income noiPrior1YTDDuration34559000JPY
Dividends income noiCurrentYTDDuration41988000JPY
Commission fee noiPrior1YTDDuration6895000JPY
Commission fee noiCurrentYTDDuration8992000JPY
Other noiPrior1YTDDuration10954000JPY
Other noiCurrentYTDDuration5373000JPY
Non operating incomePrior1YTDDuration54705000JPY
Non operating incomeCurrentYTDDuration58840000JPY
Interest expenses noePrior1YTDDuration1318000JPY
Interest expenses noeCurrentYTDDuration1735000JPY
Commission fee noePrior1YTDDuration2244000JPY
Commission fee noeCurrentYTDDuration2225000JPY
Miscellaneous loss noePrior1YTDDuration447000JPY
Miscellaneous loss noeCurrentYTDDuration5565000JPY
Non operating expensesPrior1YTDDuration4010000JPY
Non operating expensesCurrentYTDDuration9526000JPY
Ordinary incomePrior1YTDDuration814187000JPY
Ordinary incomeCurrentYTDDuration707880000JPY
Gain on sales of noncurrent assets eiPrior1YTDDuration26000JPY
Gain on sales of noncurrent assets eiCurrentYTDDuration－JPY
Gain on sales of investment securities eiPrior1YTDDuration206000JPY
Gain on sales of investment securities eiCurrentYTDDuration－JPY
Gain on investments in partnership eiPrior1YTDDuration1446000JPY
Gain on investments in partnership eiCurrentYTDDuration－JPY
Extraordinary incomePrior1YTDDuration1679000JPY
Extraordinary incomeCurrentYTDDuration－JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 12 of 12 passed
balance sheet identityconsolidated 2022-09-30pass
balance sheet identityconsolidated 2023-06-30pass rounding
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2022-09-30pass
statement vs summary · net assetsconsolidated 2023-06-30pass
statement vs summary · net income attributable to parentconsolidated 2021-10-01/2022-06-30pass
statement vs summary · net income attributable to parentconsolidated 2022-10-01/2023-06-30pass
statement vs summary · revenueconsolidated 2021-10-01/2022-06-30pass
statement vs summary · revenueconsolidated 2022-10-01/2023-06-30pass
statement vs summary · total assetsconsolidated 2022-09-30pass
statement vs summary · total assetsconsolidated 2023-06-30pass